IG
MRNA icon

ING Group’s Moderna MRNA Stock Holding History

ING Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,251
Closed -$1.8M – 563
2024
Q4 		$1.8M Buy
+43,251
New +$2.07M 0.01% 428
2023
Q4 		– Sell
-2,936
Closed -$303K – 617
2023
Q3 		$303K Sell
2,936
-71,258
-96% -$7.95M ﹤0.01% 495
2023
Q2 		$9.01M Buy
74,194
+25,894
+54% +$3.45M 0.07% 198
2023
Q1 		$7.42M Buy
+48,300
New +$7.97M 0.07% 200
2022
Q3 		– Sell
-67,222
Closed -$9.6M – 495
2022
Q2 		$9.6M Sell
67,222
-12,148
-15% -$1.74M 0.11% 145
2022
Q1 		$13.7M Buy
79,370
+16,106
+25% +$2.71M 0.14% 118
2021
Q4 		$16.1M Buy
63,264
+26,678
+73% +$7.8M 0.14% 130
2021
Q3 		$14.1M Buy
36,586
+29,506
+417% +$10.9M 0.18% 90
2021
Q2 		$1.66M Buy
+7,080
New +$1.27M 0.03% 350

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ING Group's MRNA Position: Q1 2025 in Review

ING Group sold out of Moderna (MRNA) in Q1 2025, closing a stake of 43,251 shares — an estimated $1.8M sold.

ING Group first reported a position in MRNA in Q2 2021 and held it in 9 quarters. The position peaked at $16.1M in Q4 2021. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • ING Group reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • ING Group sold 43,251 Moderna shares in Q1 2025, an estimated $1.8M.
  • ING Group first reported a position in Moderna in Q2 2021 and held it in 9 quarters.
  • ING Group's Moderna position peaked at $16.1M in Q4 2021.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on ING Group's 13F filing for Q1 2025, filed 9 May 2025.